Using its advanced AI platform to explore immune cell activity and metabolic function, Landos has identified three novel pathways: NLRX1, LANCL2, and PLXDC2. The NLRX1 pathway works to decrease reactive oxygen species and downregulate effector immune responses. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. The PLXDC2 pathway leads to the production of IL-10 and prevention of oxidative stress when activated.
Identifying Novel
Pathways at the
Interface of Immunity
and Metabolism
We are committed to
the development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease.
Landos was established as an incredibly productive research engine, with a portfolio of three novel targets anchoring libraries of immunometabolic modulation pathways, including seven first-in-class, once-daily therapies targeting 14 indications in the immunology space. This includes our three clinical stage programs: NX-13 for Ulcerative Colitis and Crohn’s Disease; Omilancor for Ulcerative Colitis, Crohn’s Disease and Eosinophilic Esophagitis; and LABP-104 for Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
Reprogramming Immune Responses in Autoimmune Disease
Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD
For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.
